Abstract
T2* Magnetic Resonance Imaging (MRI) technique allows noninvasive quantification of organ-specific iron burden, playing a key role in the management of thalassemia major (TM) patients. There are few data on the incidence of heart failure and arrhythmias in TM patients according to baseline T2* values. The aim of this study was to establish prospectively the risk of cardiac complications in a large cohort of well-treated TM patients.
We considered 527 TM patients (252 males, mean age 30±9) for who clinical data relative to a period of 5 years after the first MRI were collected in a central data base. At time of the first scan mean ferritin levels were1653±1559 ng/l, global heart was 27±13 ms, and excellent/good level of compliance were present in the 96% of the study population.
At 5 years of follow-up, we recorded 24 cardiac events: 4 episodes of cardiac failure, 15 of arrhythmia, 1 of pulmonary hypertension and 4 of other cardiac complications. The majority of these events (21/24) happened within the first 24 months subsequent to the MRI, so we considered this follow-up period. At the first MRI scan, in patients with cardiac complications the global heart T2* was 22.5 ±12.4 ms. In comparison with global heart T2* values ≥20 ms, there was not a significantly increased risk of cardiac complications associated with global heart T2* values <20 ms (HR= 2.028 P=0.09) (see figure). In the heart failure patients the global heart T2* was 19±12 ms. In comparison with global heart T2* values ≥20 ms, there was not a significantly increased risk of heart failure associated with global heart T2* values <20 ms (HR=1.9 P=0.524) or <10 ms (HR=2.6 P=0.443).
In the arrhythmic patients the global heart T2* was 25±13 ms. In comparison with global heart T2* values ≥20 ms, there was not a significantly increased risk of arrhythmia associated with global heart T2* values <20 ms (HR=2.1 P=0.179) or <10 ms (HR=0.8 P=0.824). During the follow up changes in the chelation therapy (type and/or dose-frequencies) were found in > 25% of the study population.
We detected very few cardiac events, almost all concentrated in the first 24 months. In a large cohort of well-treated TM patients heart T2* lost its power in predicting cardiac events probably due to a patient-specific adjustment of the chelation therapy MRI-guided.
No relevant conflicts of interest to declare.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/21/10.1182_blood.v118.21.1089.1089/5/m_permbld2009abs03.jpeg?Expires=1724189171&Signature=qyia0T8OTubTb~QTk1puDy76Z4iyrbJ9pt6MXgOAkVCRbmJuLLOsO0JhQ2H2fB8wiTYTvJ1c1czRwlS-hPNSCWjitIvX1BPZxgO3yYdRGzXJ8c-hBq2aUWVrvtUnJddgx~6ljkgGEPdOLClBEsB0tNrC4BfyS6-K-6Zn7NTewHVpUxExdn9QcWoLPbQxzELHBBadeh5-pww4Ii2WL1iWzmS~amoNH5mWfKUnJy96rlMJ-R3JIVo377kKUuIjY73la4fBwET7Sv~iEUnFIIlS3jNDHYfbJ7FTiQD8jlFZhSnWwj70wwqIgYbjAAe9kpGXdm1Ru0OogKeTyL98QDl1gg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes a clinically relevant abstract
Author notes
Asterisk with author names denotes non-ASH members.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal